David A. Siegel Xenon Pharmaceuticals Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 273,700 shares of XENE stock, worth $10.8 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

273,700

Previous 208,900 31.02%

Holding current value

$10.8 Million

Previous $8.15 Million 32.23%

% of portfolio

0.03%

Previous 0.02%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$36.12 - $43.96 $2.34 Million - $2.85 Million	64,800 Added 31.02%	273,700 $10.8 Million
Q2 2024 Aug 14, 2024	SELL	$36.25 - $43.75 $735,875 - $888,125	-20,300 Reduced 8.86%	208,900 $8.15 Million
Q1 2024 May 15, 2024	SELL	$42.66 - $50.04 $1 Million - $1.18 Million	-23,500 Reduced 9.3%	229,200 $9.87 Million
Q4 2023 Feb 14, 2024	BUY	$28.7 - $46.46 $5.39 Million - $8.73 Million	187,800 Added 289.37%	252,700 $11.6 Million
Q3 2023 Nov 14, 2023	BUY	$34.16 - $39.73 $2.22 Million - $2.58 Million	64,900 New	64,900 $2.22 Million
Q4 2022 Feb 14, 2023	SELL	$33.06 - $39.43 $2.26 Million - $2.69 Million	-68,300 Reduced 75.05%	22,700 $895,000
Q3 2022 Nov 14, 2022	BUY	$30.79 - $39.82 $1.19 Million - $1.54 Million	38,700 Added 74.0%	91,000 $3.29 Million
Q2 2022 Aug 15, 2022	SELL	$25.44 - $35.16 $1.79 Million - $2.48 Million	-70,400 Reduced 57.38%	52,300 $1.59 Million
Q1 2022 May 16, 2022	SELL	$25.09 - $33.13 $97,851 - $129,207	-3,900 Reduced 3.08%	122,700 $3.75 Million
Q4 2021 Feb 14, 2022	SELL	$15.6 - $35.4 $767,520 - $1.74 Million	-49,200 Reduced 27.99%	126,600 $3.96 Million
Q3 2021 Nov 15, 2021	BUY	$14.86 - $19.45 $1.38 Million - $1.8 Million	92,800 Added 111.81%	175,800 $2.69 Million
Q2 2021 Aug 16, 2021	SELL	$16.81 - $20.0 $99,178 - $118,000	-5,900 Reduced 6.64%	83,000 $1.55 Million
Q1 2021 May 17, 2021	SELL	$13.65 - $21.31 $131,040 - $204,576	-9,600 Reduced 9.75%	88,900 $1.59 Million
Q4 2020 Feb 16, 2021	SELL	$9.49 - $16.04 $68,328 - $115,488	-7,200 Reduced 6.81%	98,500 $1.52 Million
Q3 2020 Nov 16, 2020	BUY	$10.82 - $13.35 $51,936 - $64,080	4,800 Added 4.76%	105,700 $1.17 Million
Q2 2020 Aug 14, 2020	BUY	$10.21 - $14.9 $381,854 - $557,260	37,400 Added 58.9%	100,900 $1.27 Million
Q1 2020 May 15, 2020	BUY	$8.08 - $17.57 $245,632 - $534,128	30,400 Added 91.84%	63,500 $720,000
Q4 2019 Feb 14, 2020	BUY	$8.11 - $14.65 $50,282 - $90,830	6,200 Added 23.05%	33,100 $434,000
Q3 2019 Nov 14, 2019	SELL	$8.74 - $10.51 $49,818 - $59,907	-5,700 Reduced 17.48%	26,900 $242,000
Q2 2019 Aug 14, 2019	SELL	$8.51 - $10.75 $38,295 - $48,375	-4,500 Reduced 12.13%	32,600 $321,000
Q1 2019 May 15, 2019	BUY	$6.39 - $10.42 $5,751 - $9,378	900 Added 2.49%	37,100 $377,000
Q4 2018 Feb 14, 2019	BUY	$5.61 - $12.62 $203,082 - $456,844	36,200 New	36,200 $228,000

Others Institutions Holding XENE

# of Institutions

212

Shares Held

70.2M

Call Options Held

88.3K

Put Options Held

28.8K

View Full List

About Xenon Pharmaceuticals Inc.

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.45B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

More about XENE

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account